Korean J healthc assoc Infect Control Prev 2021; 26(1): 3-15
Published online June 30, 2021 https://doi.org/10.14192/kjicp.2021.26.1.3
Copyright © Korean Society for Healthcare-associated infection Control and Prevention
Department of Infectious Diseases, Ajou University School of Medicine1, Department of Endocrinology and Metabolism, Ajou University School of Medicine2, Suwon, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0).
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic. Given the urgent need for vaccines against COVID-19, huge financial investments and global scientific collaborations have been made to develop effective and safe vaccines. To date, WHO has included five COVID-19 vaccines, comprising BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca), Ad26.COV2.S (Johnson and Johnson’s Janssen), and BBIBP-CorV (Sinopharm) under WHO Emergency Use Listing as they are considered to meet the necessary criteria for safety and efficacy. In Korea, the Pfizer-BioNTech vaccine and AstraZeneca vaccine have been administered since February 2021, and three more COVID-19 vaccines are scheduled for incorporation till the end of 2021. This article focuses on the clinical and technical considerations of COVID-19 vaccinations to provide accurate and safe guidance for healthcare practitioners. A brief review of COVID-19 vaccines to be introduced in Korea is also summarized.
Keywords: COVID-19 , COVID-19 vaccines , COVID-19 pandemics